Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

UCB At a Glance

Highlights

Highlights

Ra Pharma

 

Engage Therapeutics: Staccato®Alprazolam

UCB successfully completed the acquisition of Ra Pharmaceuticals, Inc., making Ra Pharma now a wholly-owned subsidiary of UCB. This enhances our leadership potential for improving treatment options for people living with myasthenia gravis and other rare diseases.

 

UCB acquired Engage Therapeutics, Inc. a clinical-stage pharmaceutical company developing Staccato®Alprazolam for the rapid termination of epileptic seizures. This product combines the Staccato® delivery technology with the established benzodiazepine alprazolam.

   

Ferring Pharmaceuticals

 

Roche and Genentech

UCB and Ferring Pharmaceuticals Inc. entered into a co-promotion agreement to commercialize the prefilled syringe formulation Cimzia® (certolizumab pegol) in the United States for the treatment of Crohn’s disease.

 

UCB entered into a worldwide, exclusive license agreement with Roche and Genentech, a member of the Roche Group, for the global development and commercialization of bepranemab (UCB0107) in Alzheimer’s disease (AD).

   

Cimzia® available to Japanese patients

 

Handl Therapeutics and Lacerta Therapeutics

Cimzia® (certolizumab pegol) was approved by the Japanese health authorities for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma for which existing treatment methods are not sufficiently effective. This makes Cimzia® the first Fc-free, PEGylated anti-TNF treatment option now available for these patients in Japan.

 

UCB acquired Handl Therapeutics BV, a rapidly growing and transformative gene therapy company based in Leuven, Belgium and began a new collaboration with Lacerta Therapeutics, a U.S.-based clinical stage gene therapy company. Together, these will help to accelerate UCB’s ambitions in gene therapy.

   

Promising progress for bimekizumab

 

Broadening the patient population for Vimpat®

Phase 3b study BE RADIANT, comparing bimekizumab to secukinumab for the treatment of adults with moderate-to-severe plaque psoriasis met its primary end points. 

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) accepted marketing application submissions for bimekizumab for the treatment of adults with moderate-to-severe plaque psoriasis.

 

We received new approvals for Vimpat® (lacosamide) in the U.S., Europe and Japan as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older. In addition, Vimpat® oral solution was approved in China for the adjunctive treatment of partial onset seizure in epilepsy patients four years of age and older.